Current experimental vaccines based on the HIV envelope glycoprotein (Env) have failed to produce broadly neutralizing antibody responses, despite the fact that HIV-infected individuals can generate such antibodies. This discrepancy suggests that current Env immunogens may not adequately mimic native Env. This project attempts to understand Env structure with respect to antibody binding and the generation of neutralizing antibodies. First, we are attempting to define the antigenic structure of various Env immunogens using known broadly neutralizing antibodies and other defined anti-Env sera. Second, we are making novel Env immunogens to test whether focusing the immune response on specific conserved, functional structures will generate broadly neutralizing antibodies. The antibodies raised by the defined Env subdomains will further be used to map Env immunogens and regions involved in conformational changes. This approach has already demonstrated success in raising structure specific antibodies to Env that preferentially react with different conformations of Env as it undergoes changes during virus entry.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BI005010-01
Application #
6293697
Study Section
Special Emphasis Panel (LAIR)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost